The FLT3 N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Sunil Kumar JoshiJanét PittsenbargerVanessa E KennedyCheryl A C PeretzAlexander E PerlCatherine C SmithJeffrey W TynerBrian J DrukerElie TraerPublished in: American journal of hematology (2023)